Cargando…

Value of serum calcitonin estimation in clinical oncology.

In 132 consecutive patients with carcinoma of various organs, a higher serum immunoreactive calcitonin (ICT) concentration (median level 50 pg/ml) was found than in 68 normal subjects (median level 20 pg/ml). The incidence of hypercalcitoninaemia was 40%. All 9 patients with primary liver-cell carci...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, H., Hackeng, W. H., Silberbusch, J., den Ottolander, G. J., van der Meer, C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1981
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010708/
https://www.ncbi.nlm.nih.gov/pubmed/7248159
_version_ 1782136378403848192
author Mulder, H.
Hackeng, W. H.
Silberbusch, J.
den Ottolander, G. J.
van der Meer, C.
author_facet Mulder, H.
Hackeng, W. H.
Silberbusch, J.
den Ottolander, G. J.
van der Meer, C.
author_sort Mulder, H.
collection PubMed
description In 132 consecutive patients with carcinoma of various organs, a higher serum immunoreactive calcitonin (ICT) concentration (median level 50 pg/ml) was found than in 68 normal subjects (median level 20 pg/ml). The incidence of hypercalcitoninaemia was 40%. All 9 patients with primary liver-cell carcinoma were hypercalcitoninaemic. On the other hand, none of the 7 patients with a carcinoma of the breast had raised ICT levels. In bronchogenic cancer a relationship between ICT and cell type was found, with a predominance of high ICT in patients with oatcell and other undifferentiated types, whereas in squamous-cell carcinomas and adenocarcinomas of the lung hypercalcitoninaemia was relatively rare. When we divided all our patients according to differentiation of the tumour cell, it was found that the lower the degree of differentiation, the higher the ICT concentration, whereas opposite results were observed for CEA. When ICT and CEA were estimated concurrently, we found at least one marker increased in 70% of our patients. Our results demonstrate that patients with metastases in the liver have more frequently and increased ICT. In addition, we conclude that lifespan can be expected to be lower in patients with high ICT levels. In a longitudinal study of 46 patients, there was a positive correlation between change in serum ICT and tumour mass.
format Text
id pubmed-2010708
institution National Center for Biotechnology Information
language English
publishDate 1981
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20107082009-09-10 Value of serum calcitonin estimation in clinical oncology. Mulder, H. Hackeng, W. H. Silberbusch, J. den Ottolander, G. J. van der Meer, C. Br J Cancer Research Article In 132 consecutive patients with carcinoma of various organs, a higher serum immunoreactive calcitonin (ICT) concentration (median level 50 pg/ml) was found than in 68 normal subjects (median level 20 pg/ml). The incidence of hypercalcitoninaemia was 40%. All 9 patients with primary liver-cell carcinoma were hypercalcitoninaemic. On the other hand, none of the 7 patients with a carcinoma of the breast had raised ICT levels. In bronchogenic cancer a relationship between ICT and cell type was found, with a predominance of high ICT in patients with oatcell and other undifferentiated types, whereas in squamous-cell carcinomas and adenocarcinomas of the lung hypercalcitoninaemia was relatively rare. When we divided all our patients according to differentiation of the tumour cell, it was found that the lower the degree of differentiation, the higher the ICT concentration, whereas opposite results were observed for CEA. When ICT and CEA were estimated concurrently, we found at least one marker increased in 70% of our patients. Our results demonstrate that patients with metastases in the liver have more frequently and increased ICT. In addition, we conclude that lifespan can be expected to be lower in patients with high ICT levels. In a longitudinal study of 46 patients, there was a positive correlation between change in serum ICT and tumour mass. Nature Publishing Group 1981-06 /pmc/articles/PMC2010708/ /pubmed/7248159 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Mulder, H.
Hackeng, W. H.
Silberbusch, J.
den Ottolander, G. J.
van der Meer, C.
Value of serum calcitonin estimation in clinical oncology.
title Value of serum calcitonin estimation in clinical oncology.
title_full Value of serum calcitonin estimation in clinical oncology.
title_fullStr Value of serum calcitonin estimation in clinical oncology.
title_full_unstemmed Value of serum calcitonin estimation in clinical oncology.
title_short Value of serum calcitonin estimation in clinical oncology.
title_sort value of serum calcitonin estimation in clinical oncology.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010708/
https://www.ncbi.nlm.nih.gov/pubmed/7248159
work_keys_str_mv AT mulderh valueofserumcalcitoninestimationinclinicaloncology
AT hackengwh valueofserumcalcitoninestimationinclinicaloncology
AT silberbuschj valueofserumcalcitoninestimationinclinicaloncology
AT denottolandergj valueofserumcalcitoninestimationinclinicaloncology
AT vandermeerc valueofserumcalcitoninestimationinclinicaloncology